Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets
Open Access
- 19 November 2020
- journal article
- review article
- Published by Springer Nature in npj Precision Oncology
- Vol. 4 (1) , 1-7
Abstract
Abnormal activity of oncogenic and tumor-suppressor signaling pathways contributes to cancer and cancer risk in humans. Transcriptional dysregulation of these pathways is commonly associated with tumorigenesis and the development of cancer. Genetic and epigenetic alterations may mediate dysregulated transcriptional activity. One of the most important epigenetic alternations is the non-coding regulatory element, which includes both enhancers and super-enhancers (SEs). SEs, characterized as large clusters of enhancers with aberrant high levels of transcription factor binding, have been considered as key drivers of gene expression in controlling and maintaining cancer cell identity. In cancer cells, oncogenes acquire SEs and the cancer phenotype relies on these abnormal transcription programs driven by SEs, which leads to cancer cells often becoming addicted to the SEs-related transcription programs, including prostate cancer. Here, we summarize recent findings of SEs and SEs-related gene regulation in prostate cancer and review the potential pharmacological inhibitors in basic research and clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China (grand No. 82072851, 81872100 and 81772756)
- Natural Science Foundation of Tianjin Municipality (grand No. 18PTLCSY00030 and 19JCYBJC24900)
This publication has 118 references indexed in Scilit:
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome processThe EMBO Journal, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- ETS gene fusions in prostate cancerNature Reviews Urology, 2009
- Prostate cancerThe Lancet, 2008
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific TranscriptionCell, 2008
- Mammalian cyclin-dependent kinasesTrends in Biochemical Sciences, 2005
- Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturationDevelopment, 2005